Replimune Group, Inc. presented data at the 2025 ASCO Annual Meeting indicating that RP1 combined with nivolumab yielded strong responses in melanoma patients who had previously failed anti-PD-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results